J&J | JNJ - Zinsaufwendungen Für Schuld

Aktienkurs
227.35
Täglich Wechseln
-0.44 -0.19%
Monatlich
-6.24%
Jährlich
45.45%
Q2 Prognose
222.63




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 714M 26M 2025-12
Abbott USD 68M 26M 2026-03
Amgen USD 653M 32M 2025-12
AstraZeneca USD 484M 181M 2025-12
Baxter International USD 58M 14M 2025-09
Bayer EUR 675M 87M 2025-12
Becton, Dickinson and Co. USD 153M 2M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Boston Scientific USD 90M 0 2026-03
Bristol-Myers Squibb USD 432M 48M 2025-12
CONMED USD 7.37M 236K 2025-12
Cooper Companies USD 22.4M 2M 2025-12
Dexcom USD 4.7M 0 2025-09
Edwards Lifesciences USD 35.9M 2.7M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Globus Medical USD 17K 5.1B 2025-12
Insulet USD 9.2M 2.2M 2025-12
Integra LifeSciences USD 23.67M 953K 2025-12
Intuitive Surgical USD 20.11B 58.39B 2026-03
J&J USD 43M 25M 2026-03
Medtronic USD 181M 0 2025-12
Merck USD 412M 85M 2025-12
Merit Medical Systems USD 6.36M 390K 2025-12
Novartis USD 304M 23M 2025-12
Pfizer USD 711M 59M 2025-12
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 178M 203M 2026-03
Stryker USD 157M 46.17B 2025-09
Tandem Diabetes Care USD 2.07M 872.58M 2025-12
Teva Pharmaceutical Industries USD 216M 4M 2026-03
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Zimmer Biomet Holdings USD 68.8M 3.1M 2026-03
Zoetis USD 57M 1000K 2025-12